# A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

> **NCT01450696** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 296 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT01450696
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-08
- **Target enrollment:** 296 (ACTUAL)
- **Why stopped:** futility following planned interim analysis
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450696, "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01450696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*